"For those who want to dig into the numbers, Alberto Espay at the University of Cinncinati has an infographic that walks through the details of the trial results in patients with mild cognitive impairment. The key take-home? Benefits are likely to be imperceptible and the risk of brain bleeds (ARIA) and other side effects with the drug—like with aducanumab—are substantial."
#Alzheimer #alzheimersdisease #alzheimers

https://www.thenation.com/article/society/alzheimers-drugs/